MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease

Size: px
Start display at page:

Download "MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease"

Transcription

1 MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease

2 Outline of Today s Lecture Why is Alzheimer s disease a problem? What is Alzheimer s Disease? What causes Alzheimer s disease? How can we test whether something causes the disease? How can we try to interfere with the cause? (i.e. develop a drug to treat the disease) How can we quickly and safely test whether the drug may work? Kevin Jones

3 Learning Goals for Lecture Explain how genes, molecules, cells, and neural circuits interact in the generation of several neurodegenerative disorders. a. Recognize symptoms of major neurodegenerative disorders b. Apply understanding of functional neural anatomy to predict the location of degeneration, based on symptoms. c. Identify uses of forward and reverse genetics in defining the molecular basis for neurodegenerative disorders. d. Recognize gene mutations associated with major neurodegenerative disorders and the effects of those mutations on proteins they encode e. Describe how a gene mutation may lead to molecular mechanisms of pathogenesis in neurodegenerative disorders. f. Predict potential strategies for developing successful treatments for different neurodegenerative disorders. g. Use information about the molecular basis of neurodegeneration to distinguish between treatments that affect symptoms versus influence the underlying cause of a neurodegenerative disorder. h. Outline the steps of bringing a logical treatment for a neurodegenerative disorder to clinical trial

4 Alzheimer s Disease- an epidemic in progress

5 progression Plaques and tangles (shown in the blue-shaded areas) tend to spread through the cortex in a predictable pattern as Alzheimer s disease progresses. The rate of progression varies greatly. People with Alzheimer s live an average of eight years, but some people may survive up to 20 years. The course of the disease depends in part on age at diagnosis and whether a person has other health conditions. Earliest Alzheimer's changes may begin 20 years or more before diagnosis. Mild to moderate Alzheimer stages generally last from 2-10 years. Severe Alzheimer s may last from 1-5 years. From

6

7 What Causes Alzheimer s Disease? Alois Alzheimer, a German doctor, published a paper in 1907 describing the case of a woman having dementia. After she died, he had autopsied her and found deposits in her brain. The deposits are called Amyloid Plaques and Neurofibrillary Tangles Amyloid Plaque Neurofibrillary Tangles

8 The genetics of Early-Onset Familial Alzheimer s Disease Mutations were found in the following genes: Presenilin-1 Presenilin-2 The Presenilins are membrane proteins involved in proteolytic processingthought to be γ-secretase components Amyloid Precursor Protein (βapp) This is the protein that is processed to give the β- amyloid peptide βapp mutations account for less than 0.1% of total AD cases but have virtually complete penetrance

9 Proteolytic Processing of the Amyloid Precursor Protein Generates β-amyloid peptide Processing Pathways: 1- α + γ secretases gives p3 peptide 2- β + γ secretases gives β40 peptide 3- β + γ secretases gives β42 peptide- insoluble Presenilin-1 is necessary for γ secretase activity!

10 Mutations in the β-amyloid Precursor Gene Donald L. Price, * Sangram S. Sisodia, David R. Borchelt Science Volume 282, Number 5391, Issue of 6 Nov 1998, pp

11 The Amyloid Hypothesis Production of Aβ (especially the relatively insoluble Aβ42) Formation of extracellular deposits Neuron atrophy and death =Alzheimer s disease According to this hypothesis, FAD mutations enhance the production of Aβ42

12 A current view of AD progression Preclinical phase- pathological changes occurring in cells not yet apparent in neurological testing- biomarkers can detect with false positives and negatives Mild Cognitive Impairment (MCI)- neurological symptoms apparent, imaging and biomarkers can detect alterations more reliably (CSF low Aβ high tau), plaques apparent but not strongly correlated w/ degree of impairment Dementia- profound neurological symptoms, rapid decline, not associated with pronounced increase in plaque burden but tangles more apparent

13

14 Why care about biomarkers like this? A- the graphs are pretty so it makes lecture more entertaining B- they allow an exact diagnosis C- they help with diagnosis and could prove useful in treating early D- they allow promptly institutionalizing individuals with Alzheimer s

15

16 The Amyloid Hypothesis Selkoe, 2002 Science

17

18 Current Alzheimer s Therapeutics Cholinesterase Inhibitors The U.S. Food and Drug Administration (FDA) has approved two classes of drugs to treat cognitive symptoms of Alzheimer s disease. The first Alzheimer medications to be approved were cholinesterase inhibitors: Three of these drugs are commonly prescribed: donepezil (Aricept ), approved in 1996 rivastigmine (Exelon ), approved in 2000 galantamine (approved in 2001 under the trade name Reminyl and renamed Razadyne in 2005). Memantine Memantine (Namenda ) is a drug approved in October 2003 by the FDA for treatment of moderate to severe Alzheimer s disease. Memantine is classified as an uncompetitive low-to-moderate affinity N-methyl-D-aspartate (NMDA) receptor antagonist, the first Alzheimer drug of this type approved in the United States. Source:

19 How does the use of acetylcholinesterase inhibitors to treat Alzheimer s disease relate to the mechanism you think causes the disease? A. By enhancing acetylcholine function, it should enhance the activity of circuits and make the neurons more resistant to damage B. By prolonging the existence of acetylcholine, it has more of a chance to exert its neurotrophic effects C. By enhancing the activity of acetylcholinesterase, it can degrade Aβ oligomers found in the extracellular space D. Acetylcholine can promote the formation of new excitatory synapses, helping replace those that have been lost E. Acetylcholine has no apparent relevance to the mechanisms I am thinking of

20 wikipedia.org

21 Alz.org

22 The genetics of Alzheimer s Disease Susceptibility genes- Having one ApoE4 allele- ~5x increase in risk Having 2 ApoE4 alleles- ~15x increase in risk 3 alleles at this locus (ApoE2, ApoE3, ApoE4) ApoE4 is ~15% frequency in Caucasians ApoE protein important in lipid and protein transport, cardiovascular disease somehow relevant to amyloid deposition? SORL1- amyloid processing?- association study published 1/07

23 Do you want to know your ApoE genotype? A- yes B- no, never C- not now, maybe when I reach old age

24 Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

25 The SORL1 protein directs APP into recycling endosomes, which shuttle it to the cell membrane. But when SORL1 is absent, APP goes instead to the late endosomes, where the enzymes BACE and PS1 snip out neurotoxic amyloid. Science 19 Jan 2007 p.314

26

Changes in the Brain

Changes in the Brain Alzheimer s Disease Alzheimer s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most

More information

The Biochemistry of Alzheimer s Disease K A R A B A L D W I N

The Biochemistry of Alzheimer s Disease K A R A B A L D W I N The Biochemistry of Alzheimer s Disease K A R A B A L D W I N What is Alzheimer s Disease? 2 A progressive brain disorder that damages and destroys brain cells Leads to memory loss and changes in brain

More information

Alzheimer Disease (AD)

Alzheimer Disease (AD) 1 Alzheimer Disease (AD) 2 Alzheimer's disease is a progressive degenerative disease that attacks the brain and results in impaired memory, thinking and behavior. It was first described by Dr. Alois Alzheimer

More information

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia

More information

Alzheimer s Disease. Leveraging Multiple Data Sources to Maximize the Potential for Recruitment Success. By Loni Branon

Alzheimer s Disease. Leveraging Multiple Data Sources to Maximize the Potential for Recruitment Success. By Loni Branon Alzheimer s Disease Leveraging Multiple Data Sources to Maximize the Potential for Recruitment Success By Loni Branon A2 March 2016 Leveraging Multiple Data Sources to Maximize the Potential for Recruitment

More information

Genetics of Alzheimer's Disease. Kim Kukurba, Emma Xi Li

Genetics of Alzheimer's Disease. Kim Kukurba, Emma Xi Li Genetics of Alzheimer's Disease Kim Kukurba, Emma Xi Li Overview of Alzheimer's Disease Epidemiology o Alzheimer's disease (AD) is a neurodegenerative condition. Decline in thinking and reasoning skills.

More information

The impact of Alzheimer s disease

The impact of Alzheimer s disease The impact of Alzheimer s disease Ron Petersen, MD, PhD, is Director of the Mayo Alzheimer's Disease Research Center. 2 Typical changes Typical age-related changes involve: Making a bad decision once in

More information

The impact of Alzheimer s disease. Typical changes. Problematic changes. Problematic changes. What is dementia? Typical age-related changes involve:

The impact of Alzheimer s disease. Typical changes. Problematic changes. Problematic changes. What is dementia? Typical age-related changes involve: The impact of Alzheimer s disease Ron Petersen, MD, PhD, is Director of the Mayo Alzheimer's Disease Research Center. 2 Typical changes Problematic changes Typical age-related changes involve: Making a

More information

Alzheimer's Disease: From Clinical Tragedy to Reason for Hope

Alzheimer's Disease: From Clinical Tragedy to Reason for Hope Bridgewater Review Volume 34 Issue 1 Article 4 May-2015 Alzheimer's Disease: From Clinical Tragedy to Reason for Hope Kenneth Adams Bridgewater State University, kenneth.adams@bridgew.edu Recommended Citation

More information

The impact of Alzheimer s disease

The impact of Alzheimer s disease The impact of Alzheimer s disease Ron Petersen, MD, PhD, is Director of the Mayo Alzheimer's Disease Research Center. 2 The impact of Alzheimer s disease Ron Petersen, MD, PhD, is Director of the Mayo

More information

2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease

2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease 2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease Dylan Wint, M.D. ALZHEIMER DISEASE Dylan Wint, M.D. Lou Ruvo Center for Brain Health DEFINITIONS Cognitive related to thinking,

More information

Alzheimer s Disease 2009. Alzheimer s Disease. Markets, Pipeline and Opportunities. April 2009. By John Bates Ph.D. 1 Copyright 2009 Biopharm Reports

Alzheimer s Disease 2009. Alzheimer s Disease. Markets, Pipeline and Opportunities. April 2009. By John Bates Ph.D. 1 Copyright 2009 Biopharm Reports Alzheimer s Disease Markets, Pipeline and Opportunities April 2009 By John Bates Ph.D 1 About the Author John Bates is a consultant and author in the drug markets and R&D fields. After a first degree in

More information

Pradumna Singh, M. D. Associate Professor of Neurology Meharry Medical College Adjunct Faculty Vanderbilt Medical School Chief of neurology service:

Pradumna Singh, M. D. Associate Professor of Neurology Meharry Medical College Adjunct Faculty Vanderbilt Medical School Chief of neurology service: Pradumna Singh, M. D. Associate Professor of Neurology Meharry Medical College Adjunct Faculty Vanderbilt Medical School Chief of neurology service: Nashville General Hospital 1. Age associated memory

More information

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment Dementia David Lam, MD, FRCPC, Psychiatry Assistant Clinical Professor Department of Psychiatry and Behavioural Neurosciences McMaster University Hamilton, Ontario Objectives Aging and Forgetfulness Define

More information

The impact of Alzheimer s disease

The impact of Alzheimer s disease The impact of Alzheimer s disease Ron Petersen, MD, PhD, is Director of the Mayo Alzheimer's Disease Research Center. 2 Typical changes Typical age-related changes involve: Making a bad decision once in

More information

Pathophysiology of Alzheimer Disease

Pathophysiology of Alzheimer Disease Amyvid PET/CT Scan Pathophysiology of Alzheimer Disease β-amyloid neuritic plaques (black arrows) Neurofibrillary tangles (abnormally phosphorylated tau protein) (red arrow) Temporal cortex in AD, modified

More information

What is dementia? Types of dementia. Alzheimer s disease. Vascular dementia

What is dementia? Types of dementia. Alzheimer s disease. Vascular dementia What is dementia? Dementia is the name for several conditions that lead to the progressive loss of the powers of the brain and changes in a person s behaviour. The most common change is in a person s memory,

More information

CHAPTER- 6. Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats. 1. Introduction. 2. Methods

CHAPTER- 6. Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats. 1. Introduction. 2. Methods CHAPTER- 6 Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats 1. Introduction Neurodegenerative disorders, such as AD are often characterized by the degeneration of the

More information

Alzheimer s disease. What is Alzheimer s disease?

Alzheimer s disease. What is Alzheimer s disease? Alzheimer s disease What is Alzheimer s disease? What we know about dementia and Alzheimer s disease Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible

More information

Definitions Epidemiology Diagnosis Symptoms Treatment Effects of Exercise Exercise Testing Exercise Prescription Conclusions

Definitions Epidemiology Diagnosis Symptoms Treatment Effects of Exercise Exercise Testing Exercise Prescription Conclusions By Tyruss Miller Definitions Epidemiology Diagnosis Symptoms Treatment Effects of Exercise Exercise Testing Exercise Prescription Conclusions Alzheimer's disease (AD) is a condition that destroys brain

More information

The Dementia Epidemic: An Approach to Screening and Management

The Dementia Epidemic: An Approach to Screening and Management The Dementia Epidemic: An Approach to Screening and Management Thomas Caprio, MD, MPH, MSHPE, CMD, HMDC, FACP, AGSF Associate Professor of Medicine/Geriatrics, Dentistry, Clinical Nursing, & Public Health

More information

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate

More information

DRUG APPROVAL PROCESS FOR THE TREATMENT OF ALZHEIMER S DISEASE

DRUG APPROVAL PROCESS FOR THE TREATMENT OF ALZHEIMER S DISEASE Research DRUG APPROVAL PROCESS FOR THE TREATMENT OF ALZHEIMER S DISEASE There are certain principles that should be followed when involving people with Alzheimer s disease in research. For more information,

More information

Alzheimer s Disease. Research Brief. September 2015

Alzheimer s Disease. Research Brief. September 2015 Research Brief Alzheimer s Disease September 2015 Alzheimer s disease is the most common form of dementia, constituting 60 80% of all dementia cases. In 2013, the 5 th edition of the Diagnostic and Statistical

More information

Scientists don t yet fully

Scientists don t yet fully Alzheimer s Disease Genetics FACT SHEET Scientists don t yet fully understand what causes Alzheimer s disease. However, the more they learn about this devastating disease, the more they realize that genes*

More information

Common causes of dementia

Common causes of dementia Common causes of dementia Alzheimer s disease vascular (multi-infarct etc.) dementia dementia of Parkinsonism Huntington s disease Pick s disease Creutzfeldt-Jacob disease etc. DEGENERATIVE DEMENTIA Pick

More information

What is. Alzheimer s disease?

What is. Alzheimer s disease? What is Alzheimer s disease? Contents 03 What is Alzheimer s? What is dementia? 04 Symptoms 06 Diagnosis 08 Treatments This introductory booklet aims to provide an overview of Alzheimer s disease. It is

More information

A Report on Alzheimer s Disease and Current Research. by Dr. Jack Diamond, Scientific Director Alzheimer Society of Canada

A Report on Alzheimer s Disease and Current Research. by Dr. Jack Diamond, Scientific Director Alzheimer Society of Canada A Report on Alzheimer s Disease and Current Research by Dr. Jack Diamond, Scientific Director Alzheimer Society of Canada 2005 Alzheimer Society of Canada Revised 2008 A Report on Alzheimer s Disease and

More information

Non-pharmacological Approach to the Alzheimer s Disease Patient

Non-pharmacological Approach to the Alzheimer s Disease Patient Non-pharmacological Approach to the Alzheimer s Disease Patient Dr. DeeDee Hu, PharmD National Council of Certified Dementia Practitioners Objectives Copyright 2009, National Council of Identify pitfalls

More information

Understanding Dementia

Understanding Dementia Dementia Handbook for Carers Essex Understanding Dementia What is dementia? 1 Summary of dementia symptoms 4 Medication and treatment 5 1 2 Dementia is the name for several conditions that lead to the

More information

Chapter 29. Alzheimer Disease, Self-Assessment Questions

Chapter 29. Alzheimer Disease, Self-Assessment Questions Chapter 29. Alzheimer Disease, Self-Assessment Questions 1. Common symptoms of Alzheimer disease (AD) include which of the following: A. Memory loss B. Language difficulties C. Loss of initiative D. Change

More information

What is Alzheimer s disease?

What is Alzheimer s disease? What is Alzheimer s disease? Contents Introduction 03 What is Alzheimer s? 04 Symptoms 06 Diagnosis 08 Support 14 Causes 15 Risk factors 16 Research 19 Treatments 10 02 visit: www.alzheimersresearchuk.org

More information

Local Clinical Trials

Local Clinical Trials Local Clinical Trials The Alzheimer s Association, Connecticut Chapter does not officially endorse any specific research study. The following information regarding clinical trials is provided as a service

More information

Staging and Treatment of Dementia

Staging and Treatment of Dementia Staging and Treatment of Dementia Ami Hall DO 10/25/14 1 Objectives What are the two most common types of dementias seen in a primary care office How are they staged What treatments are available Definition

More information

ANXIETY, DEPRESSION AND NEURODEGENERATIVE DISEASES: NOVEL RESULTS IN THE DISCOVERY OF THEIR PATHOMECHANISMS AND NOVEL DRUG CANDIDATES

ANXIETY, DEPRESSION AND NEURODEGENERATIVE DISEASES: NOVEL RESULTS IN THE DISCOVERY OF THEIR PATHOMECHANISMS AND NOVEL DRUG CANDIDATES ANXIETY, DEPRESSION AND NEURODEGENERATIVE DISEASES: NOVEL RESULTS IN THE DISCOVERY OF THEIR PATHOMECHANISMS AND NOVEL DRUG CANDIDATES Botond Penke University of Szeged September 25, 2008. NEUROBIOLOGICAL

More information

Biomarkers for Alzheimer's Disease in Down Syndrome

Biomarkers for Alzheimer's Disease in Down Syndrome Biomarkers for Alzheimer's Disease in Down Syndrome Brad Christian, Ph.D. Waisman Laboratory for Brain Imaging Outline Rationale for Studying AD in Down Syndrome Background of Alzheimer s Disease Biomarkers

More information

Questions/Answers on Dementia due to Alzheimer s Disease Presentation at Governor s Conference on Aging Friday, December 15, 2012 Raj C.

Questions/Answers on Dementia due to Alzheimer s Disease Presentation at Governor s Conference on Aging Friday, December 15, 2012 Raj C. Questions/Answers on Dementia due to Alzheimer s Disease Presentation at Governor s Conference on Aging Friday, December 15, 2012 Raj C. Shah, MD How many people are there in the United States? A little

More information

Alzheimer s disease. Information sheet

Alzheimer s disease. Information sheet IS27 September 2003 Information sheet Alzheimer s disease Introduction This information sheet is for people with early Alzheimer s disease who want to know more about their illness, and for carers of people

More information

Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006

Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006 Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006 Alzheimer Disease is a form of dementia that affects 5% of men and

More information

basics of alzheimer s disease What it is and what you can do

basics of alzheimer s disease What it is and what you can do basics of alzheimer s disease What it is and what you can do What is Alzheimer s disease? Alzheimer s (AHLZ-high-merz) is a disease of the brain that causes problems with memory, thinking and behavior.

More information

What is Alzheimer s disease?

What is Alzheimer s disease? alzheimers.org.uk What is Alzheimer s disease? Alzheimer s disease is the most common cause of dementia, affecting around 496,000 people in the UK. The term dementia describes a set of symptoms which can

More information

Understanding Alzheimer s Disease: It s Not Just Forgetfulness

Understanding Alzheimer s Disease: It s Not Just Forgetfulness : It s Not Just Forgetfulness Alzheimer s Disease Research 2 Alzheimer s disease affects people s memories, but it involves far more than simple forgetfulness. It is a progressive, degenerative, and incurable

More information

DISCUSSION GUIDE. Momentum in Science A 4-PART DOCUMENTARY SERIES CHANGING THE WAY AMERICA THINKS ABOUT ALZHEIMER S DISEASE

DISCUSSION GUIDE. Momentum in Science A 4-PART DOCUMENTARY SERIES CHANGING THE WAY AMERICA THINKS ABOUT ALZHEIMER S DISEASE DISCUSSION GUIDE Momentum in Science A 4-PART DOCUMENTARY SERIES CHANGING THE WAY AMERICA THINKS ABOUT ALZHEIMER S DISEASE Momentum in Science Introduction Momentum in Science is the story of many scientists

More information

Everyone has mild memory lapses from time to time. You go

Everyone has mild memory lapses from time to time. You go Coping With Memory Loss Everyone has mild memory lapses from time to time. You go from the kitchen to the bedroom to get something, only to find yourself wondering what you needed. You can t find your

More information

Dementia - Alzheimer's disease

Dementia - Alzheimer's disease Dementia - Alzheimer's disease Summary Alzheimer s disease is a physical disease of the brain with progressive damage to brain cells, which causes dementia. Alzheimer s disease is the most common form

More information

Neuropsychological Assessment of Early Cognitive Impairment in the Elderly

Neuropsychological Assessment of Early Cognitive Impairment in the Elderly Neuropsychological Assessment of Early Cognitive Impairment in the Elderly David Loewenstein PhD, ABPP/CN Professor of Psychiatry and Behavioral Sciences Department of Psychiatry, Miller School of Medicine,

More information

AGING AND END OF LIFE WEBINAR SERIES Dementia Among Adults with Down Syndrome: Individual Differences in Risk and Progression

AGING AND END OF LIFE WEBINAR SERIES Dementia Among Adults with Down Syndrome: Individual Differences in Risk and Progression AGING AND END OF LIFE WEBINAR SERIES Dementia Among Adults with Down Syndrome: Individual Differences in Risk and Progression Wayne Silverman, Ph.D. Department of Behavioral Psychology, Kennedy Krieger

More information

Alzheimer Disease. Introduction. Differential Diagnosis of Late-onset Dementia. Dementia: What Is It? Introductory article

Alzheimer Disease. Introduction. Differential Diagnosis of Late-onset Dementia. Dementia: What Is It? Introductory article Petra Nowotny, Washington University School of Medicine, Saint Louis, Missouri, USA Jennifer M Kwon, Washington University School of Medicine, Saint Louis, Missouri, USA Alison M Goate, Washington University

More information

Update on Treatment of the Dementias

Update on Treatment of the Dementias Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label

More information

Actinogen Medical Best Risk vs Reward Play in Alzheimer s Dementia

Actinogen Medical Best Risk vs Reward Play in Alzheimer s Dementia ACTINOGEN MEDICAL ACTINOGEN MEDICAL Analyst: Dirk van Dissel & Alastair Murray +618 8236 8896 Authorisation: Alan Young +618 8236 8888 RECOMMENDATION Buy Initiation of coverage PRICE $0.062 TARGET PRICE

More information

Memory: What is normal, and what is Alzheimer s?

Memory: What is normal, and what is Alzheimer s? Memory: What is normal, and what is Alzheimer s? Andrew Frank M.D. B.Sc.H. F.R.C.P.(C) Cognitive Neurologist, and Medical Director, Bruyère Memory Program Élisabeth Bruyère Hospital Ottawa, Ontario Memory:

More information

Background on Alzheimer s Disease

Background on Alzheimer s Disease DEMENTIA 12 Background on Alzheimer s Disease About Dementia Dementia is a general term for a group of brain disorders, of which Alzheimer s disease is the most common. Alzheimer s disease accounts for

More information

Wellington Parc Always There When Caring Makes A Difference

Wellington Parc Always There When Caring Makes A Difference Wellington Parc Always There When Caring Makes A Difference FAQ - Frequently Asked Questions re: Alzheimer s Disease What is Alzheimer s disease? First described by Dr. Alois Alzheimer in 1906, Alzheimer

More information

Alzheimer disease and Other Dementias. Epidemiology of Dementia. DSM Definition of Dementia. Common Causes of Dementia

Alzheimer disease and Other Dementias. Epidemiology of Dementia. DSM Definition of Dementia. Common Causes of Dementia The Brigham Department of Neurology Martin A. Samuels, M.D., Chairman Alzheimer disease and Other Dementias Martin A. Samuels, M.D. Brigham & Women s Hospital, Boston, Massachusetts DSM Definition of Dementia

More information

UPDATE ON ALZHEIMER'S DISEASE CLINICAL TRIALS

UPDATE ON ALZHEIMER'S DISEASE CLINICAL TRIALS UPDATE ON ALZHEIMER'S DISEASE CLINICAL TRIALS Laurie Ryan, PhD Program Director, Alzheimer s Disease Clinical Trials Dementias of Aging Branch Division of Neuroscience National Institute on Aging, National

More information

2015 Alzheimer s Disease Facts and Figures

2015 Alzheimer s Disease Facts and Figures 2015 Alzheimer s Disease Facts and Figures Includes a Special Report on Disclosing a Diagnosis of Alzheimer s Disease Alzheimer s Disease is the sixth-leading cause of death in the United States. more

More information

Understanding. Alzheimer s Disease. Lora, diagnosed in 2004, with her daughter, Jill.

Understanding. Alzheimer s Disease. Lora, diagnosed in 2004, with her daughter, Jill. Understanding Alzheimer s Disease Lora, diagnosed in 2004, with her daughter, Jill. What Is Alzheimer s Disease? Alzheimer s disease is a neurologic disorder that affects the brain. It causes dementia.

More information

Stroke & Alzheimer s Disease: An Inflammatory Duo

Stroke & Alzheimer s Disease: An Inflammatory Duo Stroke & Alzheimer s Disease: An Inflammatory Duo Stroke and Dementia One in 3 will experience a stroke, dementia or both 64% of persons with a stroke have some degree of cognitive impairment and up to

More information

Disclosures. Case: Ms. K. Case: Ms. K. Dementia: Considering When to Start, Stop, and Continue Medications 4/23/15. * Nothing to disclose

Disclosures. Case: Ms. K. Case: Ms. K. Dementia: Considering When to Start, Stop, and Continue Medications 4/23/15. * Nothing to disclose Dementia: Considering When to Start, Stop, and Continue Medications * Nothing to disclose Disclosures Lianne Hirano, MD UW Division of Gerontology & Geriatric Medicine 4/23/15 Current Concepts in Drug

More information

2014 Alzheimer s Disease Facts and Figures

2014 Alzheimer s Disease Facts and Figures 2014 Alzheimer s Disease Facts and Figures Includes a Special Report on Women and Alzheimer s Disease Almost two-thirds of Americans with Alzheimer s disease are women. Alzheimer s Disease is the six eading

More information

Evolving Embodiment of Risk: The case of Alzheimer s Disease

Evolving Embodiment of Risk: The case of Alzheimer s Disease Evolving Embodiment of Risk: The case of Alzheimer s Disease Dr C J Ball MRCPsych Consulting Medical Officer Gen Re Life Health London Consultant Psychiatrist South London and Maudsley NHS Trust 16 November

More information

2016 ALZHEIMER S DISEASE FACTS AND FIGURES

2016 ALZHEIMER S DISEASE FACTS AND FIGURES 2016 ALZHEIMER S DISEASE FACTS AND FIGURES Includes a Special Report on the Personal Financial Impact of Alzheimer s on Families About this report 2016 Alzheimer s Disease Facts and Figures is a statistical

More information

basics of alzheimer s disease What it is and what you can do

basics of alzheimer s disease What it is and what you can do basics of alzheimer s disease What it is and what you can do What is Alzheimer s disease? Alzheimer s (AHLZ-high-merz) is a disease of the brain that causes problems with memory, thinking and behavior.

More information

The changing diagnostic criteria for AD, including early and asymptomatic disease stages and their impact on clinical trial design

The changing diagnostic criteria for AD, including early and asymptomatic disease stages and their impact on clinical trial design The changing diagnostic criteria for AD, including early and asymptomatic disease stages and their impact on clinical trial design Eric Siemers On behalf of the EFPIA Working Group 24-25 November 2014

More information

MAJOR NEUROCOGNITIVE DISORDER DUE TO ALZHEIMER S DISEASE. Adriana M Cortes, MD

MAJOR NEUROCOGNITIVE DISORDER DUE TO ALZHEIMER S DISEASE. Adriana M Cortes, MD MAJOR NEUROCOGNITIVE DISORDER DUE TO ALZHEIMER S DISEASE Adriana M Cortes, MD Disclosure CCTA #0001 Rivistagmine Patch in Veterans with Cognitive Impairment Following TBI. Vitamin E and Memantine in Alzheimer

More information

Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease

Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease Understanding NICE guidance Information for people who use NHS services Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease NICE technology appraisal guidance advises on when and

More information

Primary Endpoints in Alzheimer s Dementia

Primary Endpoints in Alzheimer s Dementia Primary Endpoints in Alzheimer s Dementia Dr. Karl Broich Federal Institute for Drugs and Medical Devices (BfArM) Kurt-Georg-Kiesinger-Allee 38, D-53175 Bonn Germany Critique on Regulatory Decisions in

More information

The Developing Person Through the Life Span 8e by Kathleen Stassen Berger

The Developing Person Through the Life Span 8e by Kathleen Stassen Berger The Developing Person Through the Life Span 8e by Kathleen Stassen Berger Chapter 24 Late Adulthood: Cognitive Development PowerPoint Slides developed by Martin Wolfger and Michael James Ivy Tech Community

More information

Understanding Alzheimer s. Overcoming everyday challenges in Alzheimer s

Understanding Alzheimer s. Overcoming everyday challenges in Alzheimer s Understanding Alzheimer s Overcoming everyday challenges in Alzheimer s I 1 Forgetting things is a normal part of getting older and something we will all experience. However, when forgetfulness starts

More information

2013 Report. New York State Coordinating Council. For Services Related to Alzheimers Disease and. Other Dementias. Governor Andrew M.

2013 Report. New York State Coordinating Council. For Services Related to Alzheimers Disease and. Other Dementias. Governor Andrew M. 2013 Report of the New York State Coordinating Council For Services Related to Alzheimers Disease and Other Dementias to Governor Andrew M. Cuomo and the New York State Legislature Table of Contents Section

More information

Role of DHA in Cognitive Aging and Alzheimer s Disease

Role of DHA in Cognitive Aging and Alzheimer s Disease Role of DHA in Cognitive Aging and Alzheimer s Disease Michelle Keske PhD 10 November, 2008 Conflict of Interest Martek Biosciences Corporation Microalgae versus Fish Oil Algal DHA Oil Fish oil with DHA+EPA

More information

NCRAD. Silver Alert System. Keeping Persons with AD Safe SILVER ALERT:

NCRAD. Silver Alert System. Keeping Persons with AD Safe SILVER ALERT: The National Cell Repository for Alzheimer s Disease (NCRAD) is a data and specimen collection source for families with Alzheimer disease (AD) or serious memory loss. Families having two or more living

More information

PROMISING NEW TREATMENTS FOR ALZHEIMER S TARGET MULTIPLE DISEASE-RELATED PROTEINS, MAY HAVE BENEFITS FOR SEVERAL BRAIN DISEASES

PROMISING NEW TREATMENTS FOR ALZHEIMER S TARGET MULTIPLE DISEASE-RELATED PROTEINS, MAY HAVE BENEFITS FOR SEVERAL BRAIN DISEASES CONTACT: Alzheimer s Association AAIC newsroom, 202-249-4002, media@alz.org Niles Frantz, Alzheimer s Association, 312-363-8782, niles.frantz@alz.org PROMISING NEW TREATMENTS FOR ALZHEIMER S TARGET MULTIPLE

More information

Diseases of the Nervous System. Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University

Diseases of the Nervous System. Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University Diseases of the Nervous System Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University Outline A. Stress-related Disorders 1. Emotional Circuitry: Key Components 2. The Hypothalamic

More information

CRITERIA FOR MILD COGNITIVE IMPAIRMENT DUE TO AD - June 11, Mild Cognitive Impairment (MCI) due to Alzheimer s Disease Workgroup

CRITERIA FOR MILD COGNITIVE IMPAIRMENT DUE TO AD - June 11, Mild Cognitive Impairment (MCI) due to Alzheimer s Disease Workgroup CRITERIA FOR MILD COGNITIVE IMPAIRMENT DUE TO AD - June 11, 2010 Mild Cognitive Impairment (MCI) due to Alzheimer s Disease Workgroup Marilyn Albert, Johns Hopkins University (Chair) Steve DeKosky, University

More information

Alzheimer s: Unraveling the Mystery

Alzheimer s: Unraveling the Mystery Alzheimer s: Unraveling the Mystery Patricia Farish Lacey, MBA Chief Operating Officer And Douglas Panto Education and Family Services Coordinator Southeastern Virginia Chapter 1 Alzheimer s Association

More information

CRITERIA FOR AD DEMENTIA June 11, 2010

CRITERIA FOR AD DEMENTIA June 11, 2010 CRITERIA F AD DEMENTIA June 11, 2010 Alzheimer s Disease Dementia Workgroup Guy McKhann, Johns Hopkins University (Chair) Bradley Hyman, Massachusetts General Hospital Clifford Jack, Mayo Clinic Rochester

More information

Long-term benefits of galantamine (Reminyl ) in Alzheimer s disease. Michael Gold 1, Sean Lilienfeld 2, & Luc Truyen 1

Long-term benefits of galantamine (Reminyl ) in Alzheimer s disease. Michael Gold 1, Sean Lilienfeld 2, & Luc Truyen 1 Long-term benefits of galantamine (Reminyl ) in Alzheimer s disease Michael Gold 1, Sean Lilienfeld 2, & Luc Truyen 1 1 Johnson & Johnson Pharmaceutical Research and Development, Titusville, New Jersey

More information

2 Treatments. In this section. Key points: Treatments 15 Drugs to treat dementia 16 Non-drug treatments 18 Treating depression and anxiety 21

2 Treatments. In this section. Key points: Treatments 15 Drugs to treat dementia 16 Non-drug treatments 18 Treating depression and anxiety 21 14 The dementia guide In this section Key points: 15 Drugs to treat dementia 16 Non-drug treatments 18 Treating depression and anxiety 1 Call the National Dementia Helpline on 0300 11 15 Key points: There

More information

Hearth Management, LLC

Hearth Management, LLC INSIGHT INTO Alzheimer s PROVIDED AS A PUBLIC SERVICE BY Hearth Management, LLC Premier Senior Living Communities FORWARD Because of the increasing problem of Alzheimer s disease within a rapidly expanding

More information

1 in 3 seniors dies with Alzheimer s or another dementia.

1 in 3 seniors dies with Alzheimer s or another dementia. 2013 Alzheimer s disease facts and figures Includes a Special Report on long-distance caregivers 1 in 3 seniors dies with Alzheimer s or another dementia. Out-of-pocket expenses for long-distance caregivers

More information

Subject Review. p.17 Alzheimer s Disease: An Update. p.21 Diabetes Team and Glycemic Control DANIEL A. LLANO, MD, PHD

Subject Review. p.17 Alzheimer s Disease: An Update. p.21 Diabetes Team and Glycemic Control DANIEL A. LLANO, MD, PHD Subject Review p.17 DANIEL A. LLANO, MD, PHD p.21 Diabetes Team and Glycemic Control MICHAEL JAKOBY, MD, MA, FACP ANN GAREY, NP ROBERT KIRBY, MD KINGSLEY ONYEMERE, MD, MPH JAMES KUMAR, MD RENATO ALCARAZ,

More information

Diagnostik der Zukunft: Wissen wir mit Proteomik und Genomik wirklich mehr?

Diagnostik der Zukunft: Wissen wir mit Proteomik und Genomik wirklich mehr? Diagnostik der Zukunft: Wissen wir mit Proteomik und Genomik wirklich mehr? Prof. Dr. J. Wiltfang Klinik für Psychiatrie und Psychotherapie (Direktor: Prof. Dr. J. Wiltfang), Rheinische Kliniken, Universität

More information

Updates in Dementia. Eric Gierke, MD Medical Director, General Neurology Swedish Neuroscience Institute

Updates in Dementia. Eric Gierke, MD Medical Director, General Neurology Swedish Neuroscience Institute Updates in Dementia Eric Gierke, MD Medical Director, General Neurology Swedish Neuroscience Institute Disclosures: Dr. Gierke has no significant financial interest in any of the products or manufacturers

More information

NEW RESEARCH SUGGESTS MEN RECEIVE DEMENTIA-RELATED MISDIAGNOSIS MORE OFTEN THAN WOMEN

NEW RESEARCH SUGGESTS MEN RECEIVE DEMENTIA-RELATED MISDIAGNOSIS MORE OFTEN THAN WOMEN EMBARGOED FOR RELEASE UNTIL TUESDAY, JULY 26, 2016, 2:45 PM ET CONTACT: Alzheimer s Association AAIC Press Office, 416-585-3701, media@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, niles.frantz@alz.org

More information

Introduction. Special points of interest: October 2014, 1 hour

Introduction. Special points of interest: October 2014, 1 hour Alzheimer s Disease, Part 1 October 2014, 1 hour Introduction In 1901, a German physician named Alois Alzheimer observed a 51 year-old patient at the Frankfurt Asylum named Auguste Deter, who exhibited

More information

Overview of Alzheimer s and Other Dementias. Terrence Norton, MD Senior Behavioral Sciences Platteville, WI

Overview of Alzheimer s and Other Dementias. Terrence Norton, MD Senior Behavioral Sciences Platteville, WI Overview of Alzheimer s and Other Dementias Terrence Norton, MD Senior Behavioral Sciences Platteville, WI Defining dementia Effects of dementia on the brain Stages and symptoms of Alzheimer s disease

More information

医 学 生 物 学 一 般 問 題 ( 問 題 用 紙 1 枚 解 答 用 紙 2 枚 )

医 学 生 物 学 一 般 問 題 ( 問 題 用 紙 1 枚 解 答 用 紙 2 枚 ) 平 成 26 年 度 大 学 院 医 学 研 究 科 博 士 課 程 入 学 試 験 (1 回 目 ) 医 学 生 物 学 一 般 問 題 ( 問 題 用 紙 1 枚 解 答 用 紙 2 枚 ) 以 下 の 問 題 1 問 題 4のうち 二 つの 問 題 を 選 択 して 解 答 しなさい 一 つの 問 題 につき1 枚 の 解 答 用 紙 を 使 用 しなさい 紙 面 不 足 の 場 合 は 裏

More information

basics of alzheimer s disease What it is and what you can do

basics of alzheimer s disease What it is and what you can do basics of alzheimer s disease What it is and what you can do What is Alzheimer s disease? Alzheimer s (AHLZ-high-merz) is a disease of the brain that causes problems with memory, thinking and behavior.

More information

The Alzheimer s Association Moving the Science Forward

The Alzheimer s Association Moving the Science Forward The Alzheimer s Association Moving the Science Forward Keith Fargo, PhD Director of Scientific Programs James Hendrix, PhD Director of Global Science Initiatives 1 Connector Convener Funder The Global

More information

Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)

Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine) 1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s

More information

Angela M. Hill, Pharm.D., BCPP Professor of Pharmacy Practice, FAMU Pharmacy Consultant, TMH NeuroScience Center

Angela M. Hill, Pharm.D., BCPP Professor of Pharmacy Practice, FAMU Pharmacy Consultant, TMH NeuroScience Center Angela M. Hill, Pharm.D., BCPP Professor of Pharmacy Practice, FAMU Pharmacy Consultant, TMH NeuroScience Center Discuss the medication enhancements and uses of current treatment options for Alzheimer

More information

Traumatic brain injury (TBI)

Traumatic brain injury (TBI) Traumatic brain injury (TBI) A topic in the Alzheimer s Association series on understanding dementia. About dementia Dementia is a condition in which a person has significant difficulty with daily functioning

More information

Running Head: THE DETECTION OF ALZHEIMER S DISEASE: A LITERATURE 1. The Detection of Alzheimer s Disease: A Literature Review and Case Study

Running Head: THE DETECTION OF ALZHEIMER S DISEASE: A LITERATURE 1. The Detection of Alzheimer s Disease: A Literature Review and Case Study Running Head: THE DETECTION OF ALZHEIMER S DISEASE: A LITERATURE 1 The Detection of Alzheimer s Disease: A Literature Review and Case Study November 15, 2012 Detection of Alzheimer s Disease 2 Abstract

More information

Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease

Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease IS 17 October 2011 Information sheet Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease Introduction... 1 How does Reminyl work?... 1 Who might benefit?... 2 What effect might Reminyl

More information

Directing an Alzheimer s/dementia Care Unit

Directing an Alzheimer s/dementia Care Unit 9135 N. Meridian Street Suite B-4 Indianapolis, IN 46260 (317) 575-9620 (800) 272-3900 September, 2004 Funded by the Indiana State Department of Health Co-sponsored by: Indiana Association of Homes and

More information

Alzheimer s Disease: Presentation & Prognosis

Alzheimer s Disease: Presentation & Prognosis Memory Alzheimer s Disease: Presentation & Prognosis James B. Pinkston, Ph.D. Clinical Neuropsychologist March 23, 2012 What is memory?... Why is memory important?... Learning Continuity Personality Functioning

More information

Dementia. Your medicine. Information for you. Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa

Dementia. Your medicine. Information for you. Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Dementia Your medicine Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other formats

More information

Treating patients with compounds or biological agents that pass the safety-test

Treating patients with compounds or biological agents that pass the safety-test Treating patients with compounds or biological agents that pass the safety-test There are numerous medical disorders without effective treatments. It is possible that many of un-treatable conditions need

More information

Early Proposal. The Biopsychology of Memory. Early Research (1920) Neurosurgeon Wilder Penfield. Early Research 4/29/2013

Early Proposal. The Biopsychology of Memory. Early Research (1920) Neurosurgeon Wilder Penfield. Early Research 4/29/2013 Early Proposal The Biopsychology of Memory Module 13.1 Different methodologies have been used to try to figure out what regions of the brain are involved in memory functions. Pavlov learning (such as classical

More information